iTeos Therapeutics, Inc. (ITOS)

NASDAQ: ITOS · IEX Real-Time Price · USD
17.29
0.45 (2.67%)
May 27, 2022 11:06 AM EDT - Market open
Market Cap633.11M
Revenue (ttm)497.30M
Net Income (ttm)297.64M
Shares Out36.62M
EPS (ttm)7.72
PE Ratio2.24
Forward PE9.26
Dividendn/a
Ex-Dividend Daten/a
Volume96,995
Open16.79
Previous Close16.84
Day's Range16.25 - 17.49
52-Week Range16.21 - 52.43
Betan/a
AnalystsBuy
Price Target52.43 (+203.2%)
Earnings DateMay 12, 2022

About ITOS

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote a...

IndustryBiotechnology
IPO DateJul 24, 2020
Employees94
Stock ExchangeNASDAQ
Ticker SymbolITOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is 52.43, which is an increase of 203.24% from the latest price.

Price Target
$52.43
(203.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

WATERTOWN, Mass. and GOSSELIES, Belgium, May 12, 2022 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

2 weeks ago - GlobeNewsWire

7 Top-Rated Biotech Stocks to Buy for Q2

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

1 month ago - InvestorPlace

Innoskel Appoints Dr Michel Detheux as Chairman

Inno s kel Appoints Dr Michel Detheux as Chairman

1 month ago - GlobeNewsWire

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

WATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development o...

1 month ago - GlobeNewsWire

ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab -gxly) and EOS-448 combination trial and announced plans to initiate multiple regis...

2 months ago - GlobeNewsWire

iTeos to Present at the Cowen 42nd Annual Health Care Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development o...

2 months ago - GlobeNewsWire

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Other symbols:APLSEVLOGMDAMRTX
3 months ago - Zacks Investment Research

iTeos to Participate in Upcoming Investor Conferences in February

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

3 months ago - GlobeNewsWire

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

4 months ago - GlobeNewsWire

Why iTeos Therapeutics Topped the Market Today

The stock is about to become a component of a high-profile index.

4 months ago - The Motley Fool

iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

4 months ago - GlobeNewsWire

iTeos Therapeutics Set to Join S&P SmallCap 600

NEW YORK, Dec. 31, 2021 /PRNewswire/ -- iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday...

Other symbols:CNC
4 months ago - PRNewsWire

iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting a...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

5 months ago - GlobeNewsWire

MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Detlev Biniszkiewicz, Ph.D. added to MPM Investment Committee

5 months ago - Business Wire

Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge

iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

6 months ago - Zacks Investment Research

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade

The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

6 months ago - Zacks Investment Research

ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -62.42% and -68.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...

6 months ago - Zacks Investment Research

iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

- First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors

6 months ago - GlobeNewsWire

iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

6 months ago - GlobeNewsWire

iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 12, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

9 months ago - GlobeNewsWire

iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

9 months ago - GlobeNewsWire

iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

10 months ago - GlobeNewsWire

Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

Other symbols:GSK
11 months ago - Zacks Investment Research